Diadema Partners’s UroGen Pharma URGN Stock Holding History

Diadema Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$263K	Sell	7,137 -16,018	-69%	-$434K	0.03%	127
2026 Q1	$416K	Buy	23,155 +1,345	+6%	+$27K	0.07%	114
2025 Q4	$511K	Sell	21,810 -68,190	-76%	-$1.48M	0.09%	116
2025 Q3	$1.8M	Sell	90,000 -60,000	-40%	-$1.08M	0.46%	64
2025 Q2	$2.06M	Buy	150,000 +73,780	+97%	+$708K	0.63%	42
2025 Q1	$843K	Buy	76,220 +26,220	+52%	+$280K	0.22%	68
2024 Q4	$533K	Buy	+50,000	New	+$599K	0.23%	70

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Diadema Partners's URGN Position: Q2 2026 in Review

Diadema Partners reduced its UroGen Pharma (URGN) stake by 69% in Q2 2026, selling an estimated $434K and leaving 7,137 shares worth $263K. The position accounts for 0.03% of the portfolio, ranked #127.

Diadema Partners first reported a position in URGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.06M in Q2 2025. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Diadema Partners held 7,137 shares of UroGen Pharma worth $263K as of Q2 2026.
Diadema Partners sold 16,018 UroGen Pharma shares in Q2 2026, an estimated $434K.
UroGen Pharma made up 0.03% of Diadema Partners's portfolio in Q2 2026, its #127 holding.
Diadema Partners first reported a position in UroGen Pharma in Q4 2024 and has held it in 7 quarters since.
Diadema Partners's UroGen Pharma position peaked at $2.06M in Q2 2025.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.